Q-omics provides the consensus-scored GCA profile across patient tissues and cancer cell-line models. GCA expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GCA is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, GCA protein abundance shows 21,777 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KICH, and GBM as cancer lineages where GCA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCA survival associations across molecular data types. GCA RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCA RNA expression–survival associations across cancer types. High GCA expression shows unfavorable associations in KIRP and LGG, but favorable associations in MESO, SKCM, KIRC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GCA RNA expression.
This table summarizes GCA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GCA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCA shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in STAD, BLCA and CHOL. The KICH box plot shows higher GCA RNA expression in normal versus tumor tissue (log2 FC = −1.827, t-test p < 0.001).
This table shows molecular features associated with GCA in patient tissues and cancer cell lines. In patient samples, GCA shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GCA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
